The laureate of the world’s first Lipidomics Excellence Award, Prof. Dr. Anne-Claude Gavin from the University of Geneva , uses the analysis technology of Dresden based Lipotype GmbH for the next breakthrough in her lipid transfer research. The biochemist draws the world’s first molecular “map of lipid highways”, she is tracing the ways of lipid transfer between the membranes of body cells.
Henri Deda studied molecular Biotechnology at TU Dresden. At Lipotype, he developed a communication approach driven by providing access to expert knowledge to everyone.
Posts by henri.deda
The month of August came with a set of newly-published lipidomics publications which made use of Lipotype Shotgun Lipidomics.
Understanding the genetics of lipid species offers information beyond that provided by routine lipid screening, and can help improve risk prediction and treatment. In the first large-scale study, novel lipid-associated genetic variants were identified, some of which were linked with risk for cardiovascular disease, such as heart attacks and strokes. Lipotype provided the technology to measure these lipids – Lipotype Shotgun Lipidomics.
LEA, the Lipidomics Excellence Award, was founded to strengthen life sciences through lipidomics. Over the course of April, the LEA jury deliberated on the submitted projects to announce the three LEA awardees.
Good Manufacturing Practices (GMP) ensure safety and quality of pharmaceutical products. Lipotype is the worldwide first and only officially GMP certified shotgun lipidomics service provider for pharmaceutical applications.
The Paul Langerhans Institute Dresden, a partner of the DZD, and the University Hospital Carl Gustav Carus joined their forces with Lipotype GmbH and developed a new shotgun lipidomics method for the molecular profiling of brown and white adipose tissue. The results of this collaborative work have now been published in the journal ́Molecular Metabolism ́.
Technology Networks published a new introductory article on lipidomics last week. They spoke to Dr. Christian Klose about applications in the field of lipid research and to Henri Deda about LEA, the new Lipidomics Excellence Award.
Lipotype announces LEA, the Lipidomics Excellence Award, for breakthrough lipidomics projects. Call for applications is open till March 30, 2019.
Lipotype put online a new biotech & dermatology customer reference with Aldeyra Therapeutics about lipid analysis for topical dermal drug development for the treatment of ichthyosis associated with SLS.
Lipotype Shotgun Skin Lipidomics provided Aldeyra Therapeutics with lipid analysis of skin samples for identification of relevant lipid biomarkers in the Phase 2 clinical trial. Results of the skin lipidomics analysis delivered evidence for a correlation between clinical effects and those skin lipid biomarkers. Consistent with the clinical activity of reproxalap, significant dermal biomarker changes were noted in reproxalap-treated patients but not vehicle-treated patients. Cholesterol, which is significantly elevated in the skin of SLS patients, was reduced in reproxalap-treated patients more than in vehicle-treated patients.
Aldeyra Therapeutics is a biotechnology company devoted to improving lives by inventing, developing, and commercializing next-generation medicines that treat immune-mediated and metabolic diseases. Aldeyra’s lead product candidate, reproxalap (formerly called NS2), is a small molecule RASP (Reactive Aldehyde Species) inhibitor in Phase 3 clinical development for the treatment of dry eye disease, allergic conjunctivitis, noninfectious anterior uveitis, and Sjögren-Larsson syndrome. With its focus on a carefully selected range of diseases, Aldeyra Therapeutics is devoted to improving lives through outstanding innovation.
Aldeyra therapeutics announces positive results from a randomized, double-blind, vehicle-controlled clinical trial of topical dermatologic nS2 in patients with Sjögren-Larsson syndrome – Aldeyra Therapeutics, 2016